Satellos Bioscience Operating Income Over Time
| MSCL Stock | 0.81 0.03 3.57% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Satellos Bioscience Performance and Satellos Bioscience Correlation. Satellos |
Cross Equities Operating Income Analysis
Compare Satellos Bioscience and related stocks such as Biosyent, Cardiol Therapeutics, and Cannara Biotech Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RX | (600 K) | 518.1 K | 1.4 M | 2.4 M | 4.3 M | 5.1 M | 5.8 M | 6.9 M | 6.8 M | 5.4 M | 5 M | 8.2 M | 7 M | 7.5 M | 9.1 M | 10.4 M | 10.9 M |
| CRDL | (1.6 M) | (1.6 M) | (1.6 M) | (1.6 M) | (1.6 M) | (1.6 M) | (1.6 M) | (1.6 M) | (7.5 M) | (13.6 M) | (20.6 M) | (45.5 M) | (50.3 M) | (29.8 M) | (40.3 M) | (36.2 M) | (38.1 M) |
| LOVE | (1.8 M) | (1.8 M) | (1.8 M) | (1.8 M) | (1.8 M) | (1.8 M) | (1.8 M) | (1.8 M) | (10.2 M) | (11.9 M) | 299.2 K | 5 M | 12 M | 8 M | 21.8 M | 25 M | 26.3 M |
| SVA | (30.6 K) | (2.6 M) | (2.1 M) | (2.8 M) | (2.9 M) | (2.5 M) | (2.6 M) | (3.7 M) | (4 M) | (5.2 M) | (6.9 M) | (24.2 M) | (41.1 M) | (31.8 M) | (15.1 M) | (13.6 M) | (12.9 M) |
| HBP | (6.8 M) | (10.6 M) | (8.2 M) | (8.7 M) | (8.7 M) | (9.6 M) | (10.2 M) | (8.5 M) | (7.5 M) | (8.6 M) | (9.6 M) | (6.5 M) | (6.3 M) | (9.4 M) | (5.4 M) | (6.2 M) | (6.6 M) |
| MDNA | (762 K) | (762 K) | (762 K) | (762 K) | (829.1 K) | (1.2 M) | (7.7 M) | (7.4 M) | (4.7 M) | (8.2 M) | (17.2 M) | (22.3 M) | (21.6 M) | (19.7 M) | (21.6 M) | (19.5 M) | (18.5 M) |
| ZEN | (153.5 K) | (1.7 M) | (2.7 M) | (3.6 M) | (3.1 M) | (4.2 M) | (2.8 M) | (1.6 M) | (2.5 M) | (1.7 M) | (4 M) | (12.6 M) | (14.1 M) | (11.5 M) | (9.6 M) | (8.6 M) | (8.2 M) |
Satellos Bioscience and related stocks such as Biosyent, Cardiol Therapeutics, and Cannara Biotech Operating Income description
Operating Income is the amount of profit realized from Satellos Bioscience operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Satellos Bioscience is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| Satellos Bioscience | MSCL |
Specialization | Healthcare, Biotechnology |
| Business Address | Royal Bank Plaza, |
| Exchange | Toronto Exchange |
null 0.81
Other Information on Investing in Satellos Stock
Satellos Bioscience financial ratios help investors to determine whether Satellos Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Satellos with respect to the benefits of owning Satellos Bioscience security.